| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wilson CH et al. | Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. | 2004 | Ann. Transplant. | pmid:15478912 |
| Muraki Y et al. | Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. | 2011 Oct-Dec | Ann. Transplant. | pmid:22210422 |
| Boratyńska M et al. | Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. | 2006 | Ann. Transplant. | pmid:17494290 |
| Grochowiecki T et al. | A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. | 2006 | Ann. Transplant. | pmid:17494291 |
| Arreola-Guerra JM et al. | Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. | 2016 | Ann. Transplant. | pmid:26879833 |
| Rhu J et al. | Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. | 2017 | Ann. Transplant. | pmid:29180612 |
| Mocchegiani F et al. | Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. | 2014 | Ann. Transplant. | pmid:25347718 |
| Fox BD et al. | Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. | 2017 | Ann. Transplant. | pmid:29133776 |
| Rehman S et al. | Effect of different tacrolimus levels on early outcomes after kidney transplantation. | 2014 | Ann. Transplant. | pmid:24509826 |
| Legris T et al. | Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. | 2013 | Ann. Transplant. | pmid:24231646 |
| Hakeam HA et al. | Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. | 2008 | Ann. Transplant. | pmid:18566560 |
| Girman P et al. | The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. | 2001 | Ann. Transplant. | pmid:11803619 |
| Wu YJ et al. | Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:26782179 |
| Gijsen VM et al. | Tacrolimus-induced nephrotoxicity and genetic variability: a review. | 2012 Apr-Jun | Ann. Transplant. | pmid:22743729 |
| Urbanowicz T et al. | Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. | 2014 | Ann. Transplant. | pmid:25274118 |
| Czubkowski P et al. | Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. | 2014 | Ann. Transplant. | pmid:25409773 |
| Baron PW et al. | Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. | 2017 | Ann. Transplant. | pmid:28533501 |
| Aguiar D et al. | Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. | 2017 | Ann. Transplant. | pmid:28461684 |
| Ueda K et al. | Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. | 2014 | Ann. Transplant. | pmid:24535029 |
| El-Agroudy AE et al. | Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. | 2008 | Ann. Transplant. | pmid:19034223 |
| Augusto JF et al. | Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. | 2013 | Ann. Transplant. | pmid:23872516 |
| Miyata Y et al. | Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. | 2016 | Ann. Transplant. | pmid:27503662 |
| Mizuno S et al. | Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. | 2013 | Ann. Transplant. | pmid:23845965 |
| Herden U et al. | Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:26842532 |
| Basu A et al. | Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959503 |
| Fukazawa K et al. | Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959523 |
| Figurski MJ et al. | Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. | 2012 Jan-Mar | Ann. Transplant. | pmid:22466911 |
| Acott P and Babel N | BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? | 2012 Jan-Mar | Ann. Transplant. | pmid:22466913 |
| Schmid S et al. | Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. | 2014 | Ann. Transplant. | pmid:25123847 |
| Remiszewski P et al. | Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". | 2003 | Ann. Transplant. | pmid:15114933 |
| Ogura Y et al. | Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:27432248 |
| Dedinská I et al. | Waist circumference as an independent risk factor for NODAT. | 2015 | Ann. Transplant. | pmid:25791039 |
| Zahn A et al. | Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. | 2013 | Ann. Transplant. | pmid:24088725 |
| Garaix F et al. | Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. | 2018 | Ann. Transplant. | pmid:30093607 |
| WÅ‚odarczyk Z et al. | Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. | 2002 | Ann. Transplant. | pmid:12465429 |
| Matia I et al. | Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. | 2014 | Ann. Transplant. | pmid:24815872 |
| Gardiner KM et al. | Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. | 2016 | Ann. Transplant. | pmid:26729299 |
| Park S et al. | Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. | 2018 | Ann. Transplant. | pmid:29891834 |
| Rostaing L et al. | The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. | 2014 | Ann. Transplant. | pmid:25017487 |
| Jannot M et al. | Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. | 2014 | Ann. Transplant. | pmid:24999809 |
| Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
| Hošková L et al. | Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. | 2016 | Ann. Transplant. | pmid:27226081 |
| Abdel Halim M et al. | Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. | 2010 Jan-Mar | Ann. Transplant. | pmid:20305320 |
| Foroncewicz B et al. | Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. | 2014 | Ann. Transplant. | pmid:25163829 |
| Schnitzbauer AA et al. | Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. | 2015 | Ann. Transplant. | pmid:25553853 |
| Mahalati K and Kahan BD | Pharmacological surrogates of allograft outcome. | 2000 | Ann. Transplant. | pmid:11217202 |
| Garlicki M et al. | Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. | 2006 | Ann. Transplant. | pmid:17025026 |
| Van Laecke S et al. | Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. | 2017 | Ann. Transplant. | pmid:28848225 |
| Malinowski M et al. | The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. | 2009 Apr-Jun | Ann. Transplant. | pmid:19487793 |
| Kitazawa F et al. | Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. | 2017 | Ann. Transplant. | pmid:28947731 |
| Kishida N et al. | Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27956735 |
| Hirano Y et al. | Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. | 2017 | Ann. Transplant. | pmid:28798289 |
| Illsinger S et al. | Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. | 2011 Apr-Jun | Ann. Transplant. | pmid:21716189 |
| Mijal J et al. | Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. | 2002 | Ann. Transplant. | pmid:12854345 |
| Thölking G et al. | Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27003330 |
| Snell GI et al. | Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. | 2013 | Ann. Transplant. | pmid:23921892 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Schmid FX | Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. | 1993 | Annu Rev Biophys Biomol Struct | pmid:7688608 |
| Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
| Tzakis AG et al. | Intestinal transplantation. | 1994 | Annu. Rev. Med. | pmid:7515221 |
| Hanauer SB and Dassopoulos T | Evolving treatment strategies for inflammatory bowel disease. | 2001 | Annu. Rev. Med. | pmid:11160781 |
| Pratt WB | The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. | 1997 | Annu. Rev. Pharmacol. Toxicol. | pmid:9131255 |
| Nikitin AV | [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. | 2014 | Antibiot. Khimioter. | pmid:25051716 |
| Romano S et al. | FK506 binding proteins as targets in anticancer therapy. | 2010 | Anticancer Agents Med Chem | pmid:21182472 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| Jachez B et al. | Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. | 1993 | Anticancer Drugs | pmid:7683935 |
| Yamamoto M et al. | Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. | 1995 | Anticancer Drugs | pmid:7579561 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
| Pinsk V et al. | Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. | 2017 | Anticancer Res. | pmid:28551651 |
| Kalas W et al. | FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. | 2003 Mar-Apr | Anticancer Res. | pmid:12820430 |
| Harada N et al. | Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. | 2018 | Anticancer Res. | pmid:30194210 |
| Ling G et al. | Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. | 2018 | Anticancer Res. | pmid:29848681 |
| Morisaki T et al. | A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. | 2000 Sep- Oct | Anticancer Res. | pmid:11131636 |
| Gornet JM et al. | Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. | 2001 Nov-Dec | Anticancer Res. | pmid:11911319 |
| Gauthier C et al. | Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. | 2003 | Antimicrob. Agents Chemother. | pmid:12709320 |
| Del Poeta M et al. | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. | 2000 | Antimicrob. Agents Chemother. | pmid:10681348 |
| Steinbach WJ et al. | Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. | 2007 | Antimicrob. Agents Chemother. | pmid:17502415 |
| Gao L et al. | Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis. | 2017 | Antimicrob. Agents Chemother. | pmid:28923863 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Lamoth F et al. | In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. | 2013 | Antimicrob. Agents Chemother. | pmid:23165466 |
| Onyewu C et al. | Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. | 2003 | Antimicrob. Agents Chemother. | pmid:12604527 |
| Fortwendel JR et al. | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. | 2009 | Antimicrob. Agents Chemother. | pmid:19015336 |
| Lamping E et al. | Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. | 2009 | Antimicrob. Agents Chemother. | pmid:19015352 |
| Reedy JL et al. | Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. | 2006 | Antimicrob. Agents Chemother. | pmid:16569889 |
| Katiyar SK et al. | Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:23027185 |
| Vaes M et al. | Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. | 2012 | Antimicrob. Agents Chemother. | pmid:23027198 |
| Zhuang D et al. | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. | 2008 | Antimicrob. Agents Chemother. | pmid:18025114 |
| Kontoyiannis DP et al. | Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. | 2008 | Antimicrob. Agents Chemother. | pmid:18070977 |
| Hashemizadeh Z et al. | Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28923870 |
| Coilly A et al. | Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. | 2012 | Antimicrob. Agents Chemother. | pmid:22908172 |
| Gao L and Sun Y | In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. | 2015 | Antimicrob. Agents Chemother. | pmid:26303797 |
| Uppuluri P et al. | Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. | 2008 | Antimicrob. Agents Chemother. | pmid:18180354 |
| Roy J et al. | The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. | 2002 | Antimicrob. Agents Chemother. | pmid:12384349 |
| Steinbach WJ et al. | In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. | 2004 | Antimicrob. Agents Chemother. | pmid:15561883 |
| Aoki Y and Kao PN | Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10543746 |
| Dannaoui E et al. | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | 2009 | Antimicrob. Agents Chemother. | pmid:19451295 |
| Rivosecchi RM et al. | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28674051 |
| Rosenwirth B et al. | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. | 1994 | Antimicrob. Agents Chemother. | pmid:7527198 |
| Venkataramanan R et al. | Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. | 2002 | Antimicrob. Agents Chemother. | pmid:12183280 |